Madrigal Pharmaceuticals Inc stock is traded at $425.21, with a volume of 391,328. It is down -1.81% in the last 24 hours and down -8.98% over the past month. Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Previous Close:
$433.03
Open:
$434.48
24h Volume:
391,328
Relative Volume:
0.45
Market Cap:
$9.88B
Revenue:
$1.13B
Net Income/Loss:
-$309.44M
P/E Ratio:
-
EPS:
-$12.80
Net Cash Flow:
-$275.41M
1W Performance:
+6.28%
1M Performance:
-8.98%
6M Performance:
-16.67%
1Y Performance:
-19.61%
1-Day Range:
$423.19$434.48
1-Week Range:
$378.28$443.30
52-Week Range:
$353.54$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
404-380-9263Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS